Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐controlled trials

Spleen tyrosine kinase (Syk) signaling is central to phagocytosis‐based, antibody‐mediated platelet destruction in adults with immune thrombocytopenia (ITP). Fostamatinib, an oral Syk inhibitor, produced sustained on‐treatment responses in a phase 2 ITP study. In two parallel, phase 3, multicenter, randomized, double‐blind, placebo‐controlled trials (FIT1 and FIT2), patients with persistent/chronic ITP were randomized 2:1 to fostamatinib (n = 101) or placebo (n = 49) at 100 mg BID for 24 weeks with a dose increase in nonresponders to 150 mg BID after 4 weeks. The primary endpoint was stable response (platelets ≥50 000/μL at ≥4 of 6 biweekly visits, weeks 14‐24, without rescue therapy). Baseline median platelet count was 16 000/μL; median duration of ITP was 8.5 years. Stable responses occurred in 18% of patients on fostamatinib vs. 2% on placebo (P = .0003). Overall responses (defined retrospectively as ≥1 platelet count ≥50 000/μL within the first 12 weeks on treatment) occurred in 43% of patients on fostamatinib vs. 14% on placebo (P = .0006). Median time to response was 15 days (on 100 mg bid), and 83% responded within 8 weeks. The most common adverse events were diarrhea (31% on fostamatinib vs. 15% on placebo), hypertension (28% vs. 13%), nausea (19% vs. 8%), dizziness (11% vs. 8%), and ALT increase (11% vs. 0%). Most events were mild or moderate and resolved spontaneously or with medical management (antihypertensive, anti‐motility agents). Fostamatinib produced clinically‐meaningful responses in ITP patients including those who failed splenectomy, thrombopoietic agents, and/or rituximab. Fostamatinib is a novel ITP treatment option that targets an important mechanism of ITP pathogenesis.

[1]  M. Braddock,et al.  The contribution of VEGF signalling to fostamatinib‐induced blood pressure elevation , 2014, British journal of pharmacology.

[2]  J. George,et al.  Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial , 2008, The Lancet.

[3]  J. George,et al.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. , 2009, Blood.

[4]  V. Jiménez‐Yuste,et al.  Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients , 2006, Annals of Hematology.

[5]  C. Pashos,et al.  Patient-reported treatment burden of chronic immune thrombocytopenia therapies , 2012, BMC Blood Disorders.

[6]  Drew Provan,et al.  International consensus report on the investigation and management of primary immune thrombocytopenia. , 2010, Blood.

[7]  J. Bussel,et al.  Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). , 2007, Blood.

[8]  J. Stockman Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial , 2010 .

[9]  J. Bussel,et al.  Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. , 2009, Blood.

[10]  R. Mcmillan Immune thrombocytopenia. , 1983, Clinics in haematology.

[11]  S. Hummler,et al.  Advances in ITP – Therapy and Quality of Life – A Patient Survey , 2011, PloS one.

[12]  K. McCrae,et al.  Splenectomy for immune thrombocytopenia: down but not out. , 2018, Blood.

[13]  J. Semple,et al.  Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP) , 2017, Journal of clinical medicine.

[14]  D. M. van der Heijde,et al.  A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of 2 Dosing Regimens of Fostamatinib in Patients with Rheumatoid Arthritis with an Inadequate Response to a Tumor Necrosis Factor-α Antagonist , 2014, The Journal of Rheumatology.

[15]  M. Genovese,et al.  An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. , 2010, The New England journal of medicine.

[16]  J. Bussel,et al.  Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. , 2007, The New England journal of medicine.

[17]  Canary Wharf,et al.  Guideline on the clinical development of medicinal products intended for the treatment of chronic primary immune thrombocytopenia , 2014 .

[18]  A. DeFranco,et al.  A Critical Role for Syk in Signal Transduction and Phagocytosis Mediated by Fcγ Receptors on Macrophages , 1997, The Journal of experimental medicine.

[19]  M. Braddock,et al.  Prevention of fostamatinib-induced blood pressure elevation by antihypertensive agents , 2015, Pharmacology research & perspectives.

[20]  J. Bussel,et al.  A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. , 2014, Blood.

[21]  J. Leonard,et al.  The efficacy and safety of B‐cell depletion with anti‐CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura , 2004, British journal of haematology.

[22]  M. Crowther,et al.  The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. , 2011, Blood.

[23]  M. Braddock,et al.  In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib , 2015, Pharmacology research & perspectives.

[24]  J. Bussel,et al.  Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.

[25]  M. Weinblatt,et al.  Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. , 2008, Arthritis and rheumatism.

[26]  B. Djulbegovic,et al.  The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. , 2000, Archives of internal medicine.

[27]  R. Mcmillan,et al.  Long-term outcomes in adults with chronic ITP after splenectomy failure. , 2004, Blood.

[28]  M. Hou,et al.  GPIIb/IIIa autoantibody predicts better rituximab response in ITP , 2018, British journal of haematology.

[29]  J. Bussel,et al.  The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP , 2007, British journal of haematology.

[30]  M. Kawahara,et al.  Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. , 2009, Blood.

[31]  E. Neufeld,et al.  Physician decision making in selection of second‐line treatments in immune thrombocytopenia in children , 2018, American journal of hematology.

[32]  J. George,et al.  Self‐reported health‐related quality of life in adults with chronic immune thrombocytopenic purpura , 2008, American journal of hematology.

[33]  S. Vesely,et al.  Corticosteroid side‐effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives , 2009, European journal of haematology.

[34]  M. Kubo,et al.  Syk-dependent signaling pathways in neutrophils and macrophages are indispensable in the pathogenesis of anti-collagen antibody-induced arthritis. , 2012, International immunology.

[35]  Victor L. J. Tybulewicz,et al.  The SYK tyrosine kinase: a crucial player in diverse biological functions , 2010, Nature Reviews Immunology.

[36]  Gustavo Leon,et al.  Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Study , 2014, Arthritis & rheumatology.

[37]  Mindy I. Davis,et al.  Comprehensive analysis of kinase inhibitor selectivity , 2011, Nature Biotechnology.

[38]  Sumit Kunwar,et al.  Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials , 2016, Rheumatology International.

[39]  B. Aggarwal,et al.  TNF Activates Syk Protein Tyrosine Kinase Leading to TNF-Induced MAPK Activation, NF-κB Activation, and Apoptosis1 , 2004, The Journal of Immunology.

[40]  M. Genovese,et al.  OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy , 2013, Annals of the rheumatic diseases.

[41]  Eun-Ju Lee,et al.  Fostamatinib for persistent/chronic adult immune thrombocytopenia. , 2018, Immunotherapy.